In the drug development landscape, biomarkers are important tools that are used as strategic drivers of decision-making. From target engagement to safety monitoring and patient stratification, biomarkers accelerate clinical development and increase the probability of success. But not all biomarkers are created equal, and their value depends heavily on…

What Are Ligand Binding Assays (LBAs)? Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or a biologic and Anti-Drug Antibodies (ADA). Applications of…

As an emerging and growing application, spectral flow cytometry offers capabilities beyond what is possible with conventional flow. Its unique capabilities make it a powerful tool for scientists aiming to extract more information from each sample and push the boundaries of discovery. Join us in this post as we…

In a bioanalytical CRO, method development is a critical step to ensure reliable and meaningful data that meets the client’s requirements. At our KCAS Bio – Lyon site, our method development team specializes in designing and optimizing ligand-binding assay (LBA) methods tailored to our clients’ specific objectives. While…

What is immunogenicity? Immunogenicity refers to the ability of a substance, such as a New Biological Entity (NBE) or a vaccine, to provoke an immune response when administered in the body. The recognition of the substance as foreign triggers an immune response, which involves the production of antibodies and the…

KCAS Bio is engaging with the scientific community in Europe throughout the fall of 2025. From attending sessions to exhibiting at booths, our experts are ready to share knowledge, showcase our capabilities, and discuss how we can support your research across discovery and clinical development. EUROTOX 2025 CongressDate: September…

KCAS Bio is connecting with the scientific community at key U.S. events this year. Whether attending or exhibiting, our experts are ready to share insights, highlight our capabilities, and discuss how we can support your research from discovery through clinical development. NCCG Annual Meeting 2025 Date: September 22, 2025Location:…

What Are Neutralizing Antibody (NAb) Assays? Neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that play an important role in evaluating the immunogenicity, safety, and efficacy of a drug product. While most drugs carry a low risk of eliciting NAbs and do not require a validated NAb…

When it comes to drug discovery, compound screening experiments are the first big step in figuring out whether a new molecule has real therapeutic potential. But the truth is, it’s not enough to simply “run the experiment and see what happens.” The way you design the study—everything from which concentrations…

Why Sample Matrix Choice Matters Choosing the right sample matrix is one of the most critical decisions when designing a flow cytometry assay.  Each option offers unique advantages and limitations that can directly impact data quality, logistics, and study outcomes. Flow cytometry requires intact, viable cells.  The power of flow…

Why Immunogenicity in Drug Development Matters Immunogenicity, why do we keep talking about it? Immunogenicity can, in the simplest of terms, be described as a subject’s ability to generate antibodies specific to the dosed protein therapeutic. Immunogenicity can be either a wanted or unwanted reaction. Wanted immunogenicity is the desired…

If you’ve worked in drug development, you already know that the road from discovery to clinical success is long, expensive, and rarely linear. One of the most pivotal checkpoints in that journey is cytotoxicity testing. Whether you’re developing a small molecule, a biologic, or a cell therapy like CAR‑T, the…